Autopsy report · NCT02472977
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Cause of deathFutility
“Trial terminated because of lack of efficacy in the short term acute phase”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 6 months before it stopped.
- 61 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Conditions
- Solid Tumor
- Interventions
- Ulocuplumab; Nivolumab
- Participants
- 61
- Sites
- 7
- Countries
- Finland, United States
Trials that died the same way
- Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
“Trial terminated due to focus of primary therapeutic areas.” - Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
“The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and no safety concerns.” - A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
“The decision was made to prematurely discontinue this trial due to lack of efficacy.” - Phase II Study of TAEST16001 in Soft Tissue Sarcoma
“The study was terminated due to initiation of a new clinical trial with an updated study design.” - Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain
“The clinical trial has ended prematurely due to low patient recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.